EnnoDC

EnnoDC is an innovative biotech developing first-in-class, dendritic cell-targeting immunotherapies. Its core technology, the 'DC engager' platform, creates bispecific antibodies that co-engage CD40 for dendritic cell activation and a disease-specific antigen for priming, effectively functioning as an in vivo 'Antibody Mediated Vaccine' (AMV). The company has validated its approach in early infectious disease trials and is now advancing a dynamic pipeline of five candidates, with a strategic presence in both Paris and Cambridge, Massachusetts. EnnoDC represents a compelling player in the next wave of immunotherapies aiming to combine the precision of checkpoint modulators with the durable memory of vaccines.

Proprietary 'DC engager studio' for designing bispecific antibodies that co-engage CD40 on dendritic cells and a disease-specific antigen, enabling in vivo Antibody Mediated Vaccination (AMV).

EnnoDC competes in the crowded immuno-oncology space against developers of CD40 agonists (e.g., Apexigen, Alligator Bioscience), bispecific T-cell engagers, and cancer vaccine platforms. Its differentiation lies in the bispecific, dendritic cell-centric approach designed to prime de novo immune responses, a niche distinct from direct T-cell targeting or systemic immune activation.